A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.

ABSTRACT:

Objective

PARP inhibitors may work synergistically to improve the efficacy of immunotherapy in patients with epithelial ovarian cancer (EOC). We performed a parallel-arm study of tremelimumab, alone or with olaparib, in patients with recurrent EOC.

Methods

Eligibility criteria included measurable disease and progression <12 months from last platinum. Participants were randomized to Arm A (tremelimumab monotherapy, 10 mg/kg/dose intravenously [IV]) or Arm B (dose level 1 [DL1] olaparib orally 150 mg twice daily with tremelimumab IV 3 mg/kg/dose and DL2 olaparib orally 150 mg twice daily with tremelimumab IV 10 mg/kg/dose). Primary objectives were safety, change in peripheral ICOS⁺ T cells, and identification of optimal dose combination.

Results

Among 24 tota

SUBMITTER: Gaillard S 

PROVIDER: S-EPMC11993342 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature